A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer

Completed · Phase 2

Conditions studied: Prostatic Neoplasm

In brief

This is a phase II study designed to evaluate the potential clinical efficacy of thalidomide in patients with hormone-refractory prostate cancer. An important aspect of this study is to characterize the pharmacokinetics of thalidomide, as well as make correlations between the degree of angiogenesis occurring in a patient and the activity of thalidomide.

Key facts

Study ID

NCT00001446

Run by

National Cancer Institute (NCI)

People needed

64

Starts

1995-09-01

Expected to finish

2001-07-01

Last updated by the study team

2008-03-04

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

Where it is running

• National Cancer Institute (NCI) — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.